Patterns of quetiapine use in psychiatric inpatients: An examination of off-label use

Annals of Clinical Psychiatry

Volumn 20, Issue 1, 2008, Pages 15-20

  Philip, Noah S ^a   Mello, Kerry ^a   Carpenter, Linda L ^a   Tyrka, Audrey R ^a   Price, Lawrence H ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BUTLER HOSPITAL   (United States)

Author keywords

Antipsychotic; Atypical; Drug usage; Off label; Quetiapine

Indexed keywords

QUETIAPINE;

ADULT; AGITATION; ARTICLE; BIPOLAR DISORDER; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PATIENT ADMISSION; PHARMACY SERVICE, HOSPITAL; PSYCHOTIC DISORDERS; RHODE ISLAND; TREATMENT OUTCOME;

EID: 39749190543     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230701866870     Document Type: Article

References (36)

1. Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G. Offlabel indication for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry. 2004;3(4):1-10.
2. Brooke NS, Wiersgalls M, Salzman C. Atypical uses of atypical antipsychotics. Harvard Rev of Psychiatry. 2005;13:317-339.
3. Weiss E, Hummer M, Koller D, Ulmer H, Fleischhacker W. Offlabel use of antipsychotic drugs. J Clin Psychopharmacol. 2000;(6):695-698.
4. Rosenheck R, Leslie D, Sernyak M. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the department of veterans affairs. Med Care. 2001;39(3):302-308.
5. Goodnick PJ. Higher than physician desk reference (US) doses on atypical antipsychotics. Expert Opin Drug Saf. 2005;4(4):653-668.
6. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl. Practice guidelines for the treatment of patients with schizophrenia. In: American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders. 2nd ed. Arlington, VA: American Psychiatric Press;2004;249-441.
7. FDA approval letter for quetiapine for major depressive episodes of bipolar disorder. Retrieved 01/07 from http://www.accessdata.fda.gov/
8. Martin, A, Koenig, K, Scahill, L. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999;9:999-1007.
9. Schutter SJ, Van Megen HJGM, Westenberg HGM. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. J Clin Psych. 2005;66(4):540-542.
10. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder. J Clin Psych. 2006;67:1042-1046.
11. McConville, BJ, Arvanitis, LA, Thyrum, PT. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psych. 2000;61:252-260.
12. DelBello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA, Barzman DH, Nelson E, Strakowski SM. A double blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2003;45(3):305-313.
13. Goldberg, RJ. Managing psychosis-related behavioral problems in the elderly. Consult Pharm. 1997;12(Suppl C):4-10.
14. Yargic LI, Corapcioglu A, Kocabasoglu N. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. Int J Psych Clin Pract. 2004;8(4):205-211.
15. Hirschfeld R, Weisler R, Raines S, McFadden W. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double blind, placebo-controlled study. J Clin Psych. 2006;67:355-362.
16. Denys D, De Geus F, Van Megen HJGM, Westenberg HGM. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psych. 2004;65(8):1040-1048.
17. Boettger S, Breitbart W. Atypical antipsychotics in the management of delirium: a review of the empiric literature. Palliat SupportCare. 2005;3(3):227-37.
18. Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. Rev Psychiatr Neurosci. 2004;29(6):452-457.
19. Seeman S: Atypical antipsychotics. Mechanism of action. Can J Psychiatry. 2002;47:27-38.
20. Lieberman, JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis C, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
21. Allison, DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain. a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
22. Jones AM, Rak IW, Raniwalla J, Phung D, Melvin R. Weight changes in patients treated with Seroquel (quetiapine). Presented at the 38th annual meeting of the American College of Neuropsychopharmacology; Dec 12-16, 1999; Acapulco, Mexico.
23. IMS Health, National prescriptions audit. Sponsored by Astra Zeneca. Retrieved 8/06 from http://www.seroquel.com
24. Quetiapine package insert, AstraZeneca Pharmaceuticals LP. Wilmington, DE; 2005.
25. Citrome L, Jaffe A, Levine J, Lindenmayer JP. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psych. 2005;66(12):1512-1516.
26. Yatham LN. Diagnosis and management of patients with bipolar II disorder. J Clin Psych. 2005;66(1):13-17.
27. Berk M, Dodd S. Bipolar II disorder: a review. Bipolar Disord. 2005;7(1):11-21.
28. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blnd, placebo controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162(7):1351-1360.
29. Chen, H, Reeves, JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC. Off-label use of antidepressant, anticonvulsant and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psych. 2006;67:972-982.
30. Chengappa KN, Goldstein JM, Greenwood M, John V, Levine J. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther. 2003;25(2):530-541.
31. Sokolski KN, Brown BJ. Quetiapine for insomnia associated with refractory depression exacerbated by phenelzine. Ann Pharmacother. 2006;40(3):567-570.
32. Pinta ER, Taylor RE. Quetiapine addiction? (letter) Am J Psychiatry. 2007;164(1):174.
33. Waters BM, Joshi KG. Intravenous quetiapine-cocaine use ("qball") (letter). Am J Psychiatry. 2007;164(1)173-174.
34. Hussain MZ, Waheed W, Hussain S. Intravenous quetiapine abuse (letter). Am J Psychiatry. 2005;162:1755-1756.
35. Pierre JM, Shnayder I, Wirshing DA, Wirshing WC. Intranasal quetiapine abuse (letter). Am J Psychiatry. 2004;161:1718.
36. Del Paggio D. Psychotropic medication abuse in correctional facilities. The Bay Area Psychopharmacology Newsletter. 2005;8:1.